of bevacizumab and two others suffered bleeding varices feeder Hre present. Another phase of Test conducted on 45 patients with 6 cycles of capecitabine and bevacizumab treatment is provided 16 objective responses, 60 DCR median PFS of 4.1 months and the median survival time of 10.7 months. The toxicity t was mild as expected, and although it was a case of acute bleeding GSK1363089 from a peptic ulcer. Another phase of Study evaluated the combination of gemcitabine, oxaliplatin, and bevacizumab in patients with HCC 27th It may come as something of a surprise that this study is very poor results, with only two minor responses and stable disease was 5. The clinical study was based on a study examining the effect of treatment on tumor perfusion by a better contrast of the dynamic magnetic resonance imaging, which showed a transient and reversible been connected supply.
Blood tumors only after the administration of bevacizumab Concluding End despite the small number of cases F Available from the Selected come Hlten series and very different studies, we believe that bevacizumab is not an anti-cancer activity of t In HCC and that does not seem particularly by its combination with expertised gt chemotherapy. Overall, the results so far obtained with bevacizumab alone or in combination, are summarized in Table 3. On CX-5461 the other hand, bevacizumab may cause severe, even t Dlichen bleeding in these patients. Although it is expected this problem obviously inclined Using these agents in patients without varices nkt Fa esophagus and the risk of bleeding Realistic one, even without thrombocytopenia. Sunitinib, which AC keep up Experiments have on the activity of t And focused Vertr Possibility of the drug, an inhibitor of several tyrosine kinases, for HCC. A study of 37 patients, the full dose and after conventional treatment provided partial response and 13 disease stabilizations, with signs of tumor necrosis and decreased tumor perfusion in a significant number of patients.
However, the severe side effects, with h Ufigen were Grade 3 toxicity 4 th, Cases of not less than five toxic Todesf. Moreover ben CONFIRMS 27 patients a dose reduction w During treatment. Given these concerns about the safety of a full dose of medication, another attempt for 34 patients re-scheduled Oivent 37.5 mg. M RIGHTS What had been observed in renal cancer per sunitinib at this dose U as a mild anti-cancer activity of t, But only good reps Possibility, ie a decrease of the anti-cancer in a decrease of the surface Fl Under the curve of the drug. This study also showed that at least two circulating angiogenic markers IL-6 and endothelial cells Preferences shore Correlated with survival. Rational basis for future research Anything similar results in terms of efficacy and reps Opportunity were in another test on 23 patients who get again U low dose, 37.5 mg every 4 to 6 weeks. These results, in particular